Retatrutide
Also known as: LY3437943
Molecular Identifiers
Overview
Triple agonist of GLP-1, GIP, and Glucagon receptors, with a molecular weight of approximately 4,482 Da. Represents the next generation of metabolic peptides, acting on three incretin pathways simultaneously for weight and metabolism control.
In phase 3 clinical trials for the treatment of obesity and type 2 diabetes. Triple GIP/GLP-1/Glucagon agonist developed by Eli Lilly with promising results of up to 24% weight loss in phase 2.
Modified peptide — triple agonist with non-natural amino acids (Aib) and conjugated fatty acid
Half-life
~6 days
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- GLP-1 receptor agonism (satiety, glucose-dependent insulin secretion)
- GIP receptor agonism (potentiation of the incretin effect)
- Glucagon receptor agonism (hepatic lipolysis, thermogenesis, energy expenditure)
- Delayed gastric emptying
- Reduction of hepatic steatosis via glucagon receptor activation
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 0.5-12 mg per week (subcutaneous) |
| Frequency | Once per week |
| Timing | Same day and time each week |
| Duration | 24-48 weeks (with gradual dose escalation) |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
- Injection site reactions
Presentations & Preparation
Vials of Retatrutide found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: According to vial concentration
- Inject the diluent slowly against the vial wall
- Gently swirl until completely dissolved — never shake
- Mandatory gradual escalation every 4 weeks
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Retatrutide.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AICAR
50-150 mg per injection · 2-3 times per week
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly